Yushen Qian1, Erqi L Pollom1, Chika Nwachukwu1, Kira Seiger2, Rie von Eyben1, Ann K Folkins3, Elizabeth A Kidd4. 1. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 4. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: ekidd@stanford.edu.
Abstract
OBJECTIVES: Emerging evidence suggests that extent of lymphovascular space invasion (LVSI) predicts for risk of lymph node metastasis in endometrioid uterine cancers. However, this correlation remains unknown in the setting of uterine serous carcinoma (USC). We sought to examine the association between extent of LVSI and other histopathologic characteristics with risk of nodal metastasis for women with USC. MATERIALS/ METHODS: Pathological data from all cases of uterine serous carcinoma between July 1998 to July 2015 at our institution were reviewed. Descriptive, univariate, and multivariate logistic regression analysis of selected pathologic features were performed. RESULTS: 88 patients with USC underwent total abdominal or laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and selective lymphadenectomy. Surgical staging revealed the following FIGO stage distributions: I (41%), II (8%), III (32%), IV (19%). LVSI was present in 44 (50%) patients. 36 patients (41%) had LN metastases with median number of total nodes removed of 17 (range, 1-49). On univariate analysis, depth of myometrial invasion, LVSI, tumor size, and cervical stromal involvement were significantly associated with nodal involvement. In a multivariate model, LVSI (OR 6.25, 95% CI 2.2-18.0, p<0.01) and cervical stromal involvement (OR 3.33, 95% CI 1.10-10.0, p=0.03) were the only factors that remained significant. Among patients with LVSI-positive disease, extensive LVSI was associated with increased risk of nodal involvement compared to focal LVSI (90% vs 29%, p=0.04). CONCLUSIONS: Presence and extent of LVSI, and cervical stromal invasion are important predictors for lymph node metastasis in uterine serous carcinoma.
OBJECTIVES: Emerging evidence suggests that extent of lymphovascular space invasion (LVSI) predicts for risk of lymph node metastasis in endometrioid uterine cancers. However, this correlation remains unknown in the setting of uterine serous carcinoma (USC). We sought to examine the association between extent of LVSI and other histopathologic characteristics with risk of nodal metastasis for women with USC. MATERIALS/ METHODS: Pathological data from all cases of uterine serous carcinoma between July 1998 to July 2015 at our institution were reviewed. Descriptive, univariate, and multivariate logistic regression analysis of selected pathologic features were performed. RESULTS: 88 patients with USC underwent total abdominal or laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and selective lymphadenectomy. Surgical staging revealed the following FIGO stage distributions: I (41%), II (8%), III (32%), IV (19%). LVSI was present in 44 (50%) patients. 36 patients (41%) had LN metastases with median number of total nodes removed of 17 (range, 1-49). On univariate analysis, depth of myometrial invasion, LVSI, tumor size, and cervical stromal involvement were significantly associated with nodal involvement. In a multivariate model, LVSI (OR 6.25, 95% CI 2.2-18.0, p<0.01) and cervical stromal involvement (OR 3.33, 95% CI 1.10-10.0, p=0.03) were the only factors that remained significant. Among patients with LVSI-positive disease, extensive LVSI was associated with increased risk of nodal involvement compared to focal LVSI (90% vs 29%, p=0.04). CONCLUSIONS: Presence and extent of LVSI, and cervical stromal invasion are important predictors for lymph node metastasis in uterine serous carcinoma.
Authors: Ann K Folkins; Nicole S Nevadunsky; A Saleemuddin; Elke A Jarboe; Michael G Muto; Colleen M Feltmate; Chris P Crum; Michelle S Hirsch Journal: Mod Pathol Date: 2010-05-14 Impact factor: 7.842
Authors: Tjalling Bosse; Elke E M Peters; Carien L Creutzberg; Ina M Jürgenliemk-Schulz; Jan J Jobsen; Jan Willem M Mens; Ludy C H W Lutgens; Elzbieta M van der Steen-Banasik; Vincent T H B M Smit; Remi A Nout Journal: Eur J Cancer Date: 2015-06-03 Impact factor: 9.162
Authors: T Hachisuga; T Kaku; K Fukuda; F Eguchi; M Emoto; T Kamura; T Iwasaka; T Kawarabayashi; H Sugimori; M Mori Journal: Cancer Date: 1999-11-15 Impact factor: 6.860
Authors: Amanda Nickles Fader; David Starks; Paola A Gehrig; Angeles Alvarez Secord; Heidi E Frasure; David M O'Malley; Erin R Tuller; Peter G Rose; Laura J Havrilesky; Kathleen N Moore; Warner K Huh; Allison E Axtell; Joseph L Kelley; Kristine M Zanotti Journal: Gynecol Oncol Date: 2009-08-26 Impact factor: 5.482
Authors: B A Goff; D Kato; R A Schmidt; M Ek; J A Ferry; H G Muntz; J M Cain; H K Tamimi; D C Figge; B E Greer Journal: Gynecol Oncol Date: 1994-09 Impact factor: 5.482
Authors: M M AlHilli; K C Podratz; S C Dowdy; J N Bakkum-Gamez; A L Weaver; M E McGree; G L Keeney; W A Cliby; A Mariani Journal: Gynecol Oncol Date: 2013-07-09 Impact factor: 5.482
Authors: John K Chan; Renata Urban; Michael K Cheung; Jacob Y Shin; Amreen Husain; Nelson N Teng; Jonathan S Berek; Joan L Walker; Daniel S Kapp; Kathryn Osann Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: Marina Frimer; Eirwen M Miller; Viswanathan Shankar; Eugenia Girda; Keyur Mehta; Harriet O Smith; Dennis Y S Kuo; Gary L Goldberg; Mark H Einstein Journal: Int J Gynecol Cancer Date: 2018-11 Impact factor: 3.437